Skip to main content
. 2022 Mar 25;12:834761. doi: 10.3389/fonc.2022.834761

Figure 2.

Figure 2

Patient selection for the spotlight cohort from the Flatiron Health Database. aExclusion for lacking confirmation of negative test status for EGFR/ALK genomic aberration applied only to nonsquamous tumors. ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death-ligand 1.